Literature DB >> 25002085

Subterfuge and sabotage: evasion of host innate defenses by invasive gram-positive bacterial pathogens.

Cheryl Y M Okumura1, Victor Nizet.   

Abstract

The development of a severe invasive bacterial infection in an otherwise healthy individual is one of the most striking and fascinating aspects of human medicine. A small cadre of gram-positive pathogens of the genera Streptococcus and Staphylococcus stand out for their unique invasive disease potential and sophisticated ability to counteract the multifaceted components of human innate defense. This review illustrates how these leading human disease agents evade host complement deposition and activation, impede phagocyte recruitment and activation, resist the microbicidal activities of host antimicrobial peptides and reactive oxygen species, escape neutrophil extracellular traps, and promote and accelerate phagocyte cell death through the action of pore-forming cytolysins. Understanding the molecular basis of bacterial innate immune resistance can open new avenues for therapeutic intervention geared to disabling specific virulence factors and resensitizing the pathogen to host innate immune clearance.

Entities:  

Keywords:  Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; immune evasion; innate immunity

Mesh:

Year:  2014        PMID: 25002085      PMCID: PMC4343215          DOI: 10.1146/annurev-micro-092412-155711

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  138 in total

1.  Neutrophil transendothelial migration in vitro to Streptococcus pneumoniae is pneumolysin dependent.

Authors:  Jessica G Moreland; Gail Bailey
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-12-09       Impact factor: 5.464

2.  An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps.

Authors:  Katharina Beiter; Florian Wartha; Barbara Albiger; Staffan Normark; Arturo Zychlinsky; Birgitta Henriques-Normark
Journal:  Curr Biol       Date:  2006-02-21       Impact factor: 10.834

3.  RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections.

Authors:  Oscar Cirioni; Andrea Giacometti; Roberto Ghiselli; Giorgio Dell'Acqua; Fiorenza Orlando; Federico Mocchegiani; Carmela Silvestri; Alberto Licci; Vittorio Saba; Giorgio Scalise; Naomi Balaban
Journal:  J Infect Dis       Date:  2005-12-09       Impact factor: 5.226

Review 4.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

5.  Human peptidoglycan recognition protein S is an effector of neutrophil-mediated innate immunity.

Authors:  Ju Hyun Cho; Iain P Fraser; Koichi Fukase; Shoichi Kusumoto; Yukari Fujimoto; Gregory L Stahl; R Alan B Ezekowitz
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

6.  D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion.

Authors:  Sascha A Kristian; Vivekanand Datta; Christopher Weidenmaier; Rita Kansal; Iris Fedtke; Andreas Peschel; Richard L Gallo; Victor Nizet
Journal:  J Bacteriol       Date:  2005-10       Impact factor: 3.490

7.  Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense.

Authors:  George Y Liu; Kelly S Doran; Toby Lawrence; Nicole Turkson; Manuela Puliti; Luciana Tissi; Victor Nizet
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

8.  Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense.

Authors:  Sylvia Knapp; Catharina W Wieland; Cornelis van 't Veer; Osamu Takeuchi; Shizuo Akira; Sandrine Florquin; Tom van der Poll
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

9.  DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps.

Authors:  John T Buchanan; Amelia J Simpson; Ramy K Aziz; George Y Liu; Sascha A Kristian; Malak Kotb; James Feramisco; Victor Nizet
Journal:  Curr Biol       Date:  2006-02-21       Impact factor: 10.834

10.  Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes.

Authors:  Leïla Staali; Susanne Bauer; Matthias Mörgelin; Lars Björck; Hans Tapper
Journal:  Cell Microbiol       Date:  2006-04       Impact factor: 3.715

View more
  30 in total

1.  The cysteine protease ApdS from Streptococcus suis promotes evasion of innate immune defenses by cleaving the antimicrobial peptide cathelicidin LL-37.

Authors:  Fang Xie; Yanan Zan; Yueling Zhang; Ning Zheng; Qiulong Yan; Wanjiang Zhang; Huihui Zhang; Mingjie Jin; Fuguang Chen; Xinyuan Zhang; Siguo Liu
Journal:  J Biol Chem       Date:  2019-10-16       Impact factor: 5.157

2.  Humoral Immunity in the Gut Selectively Targets Phenotypically Virulent Attaching-and-Effacing Bacteria for Intraluminal Elimination.

Authors:  Nobuhiko Kamada; Kei Sakamoto; Sang-Uk Seo; Melody Y Zeng; Yun-Gi Kim; Marilia Cascalho; Bruce A Vallance; José L Puente; Gabriel Núñez
Journal:  Cell Host Microbe       Date:  2015-04-30       Impact factor: 21.023

3.  Synergistic Action of Staphylococcus aureus α-Toxin on Platelets and Myeloid Lineage Cells Contributes to Lethal Sepsis.

Authors:  Michael E Powers; Russell E N Becker; Anne Sailer; Jerrold R Turner; Juliane Bubeck Wardenburg
Journal:  Cell Host Microbe       Date:  2015-06-10       Impact factor: 21.023

Review 4.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

Review 5.  Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

Authors:  William E Sause; Peter T Buckley; William R Strohl; A Simon Lynch; Victor J Torres
Journal:  Trends Pharmacol Sci       Date:  2015-12-22       Impact factor: 14.819

6.  The Transcriptional Regulator CpsY Is Important for Innate Immune Evasion in Streptococcus pyogenes.

Authors:  Luis A Vega; Kayla M Valdes; Ganesh S Sundar; Ashton T Belew; Emrul Islam; Jacob Berge; Patrick Curry; Steven Chen; Najib M El-Sayed; Yoann Le Breton; Kevin S McIver
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

7.  Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection.

Authors:  Felipe A Pinho-Ribeiro; Buket Baddal; Rianne Haarsma; Maghnus O'Seaghdha; Nicole J Yang; Kimbria J Blake; Makayla Portley; Waldiceu A Verri; James B Dale; Michael R Wessels; Isaac M Chiu
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

Review 8.  Innate Immunity to Staphylococcus aureus: Evolving Paradigms in Soft Tissue and Invasive Infections.

Authors:  Stephanie L Brandt; Nicole E Putnam; James E Cassat; C Henrique Serezani
Journal:  J Immunol       Date:  2018-06-15       Impact factor: 5.422

9.  Discovery and Characterization of Human-Urine Utilization by Asymptomatic-Bacteriuria-Causing Streptococcus agalactiae.

Authors:  Deepak S Ipe; Nouri L Ben Zakour; Matthew J Sullivan; Scott A Beatson; Kimberly B Ulett; William H Benjamin; Mark R Davies; Samantha J Dando; Nathan P King; Allan W Cripps; Mark A Schembri; Gordon Dougan; Glen C Ulett
Journal:  Infect Immun       Date:  2015-11-09       Impact factor: 3.441

10.  Heme-Dependent Siderophore Utilization Promotes Iron-Restricted Growth of the Staphylococcus aureus hemB Small-Colony Variant.

Authors:  Izabela Z Batko; Ronald S Flannagan; Veronica Guariglia-Oropeza; Jessica R Sheldon; David E Heinrichs
Journal:  J Bacteriol       Date:  2021-10-04       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.